Hormone Replacement Therapy: Iron gets in the way

Accumulation of iron with age may inhibit the benefits of hormone replacement therapy on cardiovascular disease in late postmenopause.
  1. Kuldeep Singh
  2. Rajeev Malhotra  Is a corresponding author
  1. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, United States

Menopause is a biological process often occurring between ages 45 and 55, when egg production ceases and the menstrual cycle ends due to a decline in reproductive hormones, especially estrogen. The postmenopausal state increases the risk of cardiovascular diseases and dying from cardiac-related illnesses, such as a heart attack or stroke. For instance, previous work has shown that compared to age-matched men, premenopausal women are less prone to atherosclerosis, a formation of plaques made up of fatty deposits and other substances inside arteries. However, this protection is lost after menopause, with atherosclerosis progression being particularly prominent in late postmenopausal women over the age of 65 (Moss et al., 2019).

Some studies have suggested that the primary method for treating the symptoms of menopause, hormone replacement therapy (HRT), can also improve cardiovascular health (Herrington et al., 1999; Stampfer and Colditz, 1991). While others have reported HRT to have the opposite effect and actually increase the risk of cardiovascular disease (Hulley et al., 1998; Rossouw et al., 2002). One potential reason for these contradicting results is that HRT benefits cardiovascular health in the early stages of postmenopause but not later on (Boardman et al., 2015; Hlatky et al., 2002; Hodis et al., 2016; Rocca et al., 2014). Now, in eLife, Tong Qiao, Kuanyu Li (both at Nanjing Medical University) and colleagues – including Tianze Xu and Jing Cai as joint first authors – report what could be causing this age-related effect (Xu et al., 2023).

The team (who are based in China, Israel and Mexico) collected plaques and blood samples from atherosclerosis patients who were also postmenopause and divided them into two groups: early postmenopausal (55–65 years old) and late postmenopausal (over 65). They found that samples from the late group contained higher levels of iron and ferritin, the protein that stores iron inside cells. Late postmenopausal patients also produced less of the receptor ERα, which binds to estrogen and is critical for maintaining healthy blood vessels. This suggests that age-related accumulation of iron is negatively associated with ERα levels.

Next, Xu et al. carried out experiments in young mice that had been genetically modified to have atherosclerosis and also had their ovaries removed to trigger the symptoms of menopause. Treating the mice with a form of estrogen known as estradiol, which is used in HRT, increased ERα levels, but only in mice that were early postmenopausal. Conversely, late postmenopausal mice treated with estradiol had less ERα compared to non-treated groups. Thus, it appears that the high levels of iron in the tissues of late postmenopausal mice is somehow impairing the effects of estradiol.

To confirm this effect, Xu et al. conducted further experiments on atherosclerosis mice lacking the gene for ferroportin 1, specifically in their myeloid cells (a type of cell that will mature into certain immune cells of the blood, such as macrophages). The removal of ferroportin 1, a transmembrane protein that exports iron, leads to a buildup of iron inside macrophages. Iron-overloaded macrophages have been shown to speed up the progression of atherosclerosis, whereas macrophages with low levels of iron reduce progression of the disease (Cai et al., 2020; Malhotra et al., 2019). When the mutant mice were treated with estradiol, this resulted in larger atherosclerotic lesions in both the early and late stages of postmenopause. This suggests that iron influences how estradiol impacts atherosclerosis. The mice also had lower levels of ERα in their aortas, which was reduced even further following estradiol treatment.

Xu et al. found that high amounts of iron combined with estradiol downregulated ERα by activating Mdm2, a protein that induces ubiquitin degradation of the estrogen receptor (Figure 1). Reducing the expression of the gene coding for Mdm2 through iron chelation therapy restored ERα levels and attenuated the development of atherosclerosis in late postmenopausal mice.

Schematic representation of the proposed divergent effects of HRT treatment in postmenopause.

If hormone replacement therapy (HRT) is prescribed in the early stages of postmenopause (first 10 years), the estrogen from HRT will slow the progression of atherosclerosis (left; dark blue). Experiments in mice suggest it does this by reducing the levels of Mdm2, an enzyme that signals for the degradation of certain proteins. This results in higher levels of the receptor for estrogen, ERα, which also helps to maintain healthy blood vessels. HRT has the opposite effect when prescribed during the later stages of postmenopause (10 years or more), where it will increase the progression of atherosclerosis (right; light blue). Xu et al. propose that this is due to older individuals having higher levels of iron accumulating in their tissues, which causes estrogen to boost the amount of Mdm2 instead, resulting in lower levels of ERα and increased progression of atherosclerosis.

Overall, this study provides strong evidence that iron accumulation shifts estradiol from a drug that reduces atherosclerosis to a drug that promotes its progression. The excess iron that accumulates in older individuals promotes degradation of ERα, and this is then further amplified by estradiol treatment, counteracting the anti-atherosclerosis effects of the drug. It is important to note that this study does not directly address how HRT and iron affect the stability of atherosclerosis plaques or their chance of rupturing, which is often the cause of a heart attack or stroke.

Previous work has shown that HRT reduces mortality and coronary heart disease, but only if administered in the first 10 years post menopause (Boardman et al., 2015). The study by Xu et al. suggests that this effect may be due to iron accumulating in the blood with age. This highlights the need for clinical studies investigating how iron levels impact the benefits of HRT on cardiovascular health post menopause.

References

Article and author information

Author details

  1. Kuldeep Singh

    Kuldeep Singh is in the Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7187-4782
  2. Rajeev Malhotra

    Rajeev Malhotra is in the Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States

    For correspondence
    rmalhotra@mgh.harvard.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0120-4630

Publication history

  1. Version of Record published: August 10, 2023 (version 1)

Copyright

© 2023, Singh and Malhotra

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,328
    views
  • 22
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kuldeep Singh
  2. Rajeev Malhotra
(2023)
Hormone Replacement Therapy: Iron gets in the way
eLife 12:e90743.
https://doi.org/10.7554/eLife.90743

Further reading

    1. Cell Biology
    2. Developmental Biology
    Corey D Holman, Alexander P Sakers ... Patrick Seale
    Research Article

    The energy-burning capability of beige adipose tissue is a potential therapeutic tool for reducing obesity and metabolic disease, but this capacity is decreased by aging. Here, we evaluate the impact of aging on the profile and activity of adipocyte stem and progenitor cells (ASPCs) and adipocytes during the beiging process in mice. We found that aging increases the expression of Cd9 and other fibro-inflammatory genes in fibroblastic ASPCs and blocks their differentiation into beige adipocytes. Fibroblastic ASPC populations from young and aged mice were equally competent for beige differentiation in vitro, suggesting that environmental factors suppress adipogenesis in vivo. Examination of adipocytes by single nucleus RNA-sequencing identified compositional and transcriptional differences in adipocyte populations with aging and cold exposure. Notably, cold exposure induced an adipocyte population expressing high levels of de novo lipogenesis (DNL) genes, and this response was severely blunted in aged animals. We further identified Npr3, which encodes the natriuretic peptide clearance receptor, as a marker gene for a subset of white adipocytes and an aging-upregulated gene in adipocytes. In summary, this study indicates that aging blocks beige adipogenesis and dysregulates adipocyte responses to cold exposure and provides a resource for identifying cold and aging-regulated pathways in adipose tissue.

    1. Cell Biology
    Tongtong Ma, Ruimin Ren ... Heng Wang
    Research Article

    Current studies on cultured meat mainly focus on the muscle tissue reconstruction in vitro, but lack the formation of intramuscular fat, which is a crucial factor in determining taste, texture, and nutritional contents. Therefore, incorporating fat into cultured meat is of superior value. In this study, we employed the myogenic/lipogenic transdifferentiation of chicken fibroblasts in 3D to produce muscle mass and deposit fat into the same cells without the co-culture or mixture of different cells or fat substances. The immortalized chicken embryonic fibroblasts were implanted into the hydrogel scaffold, and the cell proliferation and myogenic transdifferentiation were conducted in 3D to produce the whole-cut meat mimics. Compared to 2D, cells grown in 3D matrix showed elevated myogenesis and collagen production. We further induced fat deposition in the transdifferentiated muscle cells and the triglyceride content could be manipulated to match and exceed the levels of chicken meat. The gene expression analysis indicated that both lineage-specific and multifunctional signalings could contribute to the generation of muscle/fat matrix. Overall, we were able to precisely modulate muscle, fat, and extracellular matrix contents according to balanced or specialized meat preferences. These findings provide new avenues for customized cultured meat production with desired intramuscular fat contents that can be tailored to meet the diverse demands of consumers.